SCHEMBL6716965

SCHEMBL6716965

Cc1c(Cl)cccc1S(=O)(=O)Nc1ccc(C2=NCCc3cc(C(F)(F)F)ccc32)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSPT1 P15170 1/20 0.43
DDB1 Q16531 1/20 0.43
CRBN Q96SW2 1/20 0.43
MCL1 Q07820 2/20 0.41
CDK1 P06493 1/20 0.41
CCNB1 P14635 1/20 0.41
CCNA2 P20248 1/20 0.41
CCND1 P24385 1/20 0.41
CDK2 P24941 1/20 0.41
CDK7 P50613 1/20 0.41
CCNH P51946 1/20 0.41
CCNA1 P78396 1/20 0.41
CDK6 Q00534 1/20 0.41
IDH1 O75874 7/20 0.40
LMNA P02545 3/20 0.40
HSD11B1 P28845 2/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA7 P43166 2/20 0.39
CA9 Q16790 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6714790 0.92 LMNA (0.47) GSPT1DDB1CRBNMCL1CDK1
SCHEMBL7213756 0.89 IDH1 (0.41) MCL1CDK1CCNB1CCNA2CCND1
SCHEMBL6714977 0.88 GSPT1 (0.45) GSPT1DDB1CRBNHSD11B1CA1
SCHEMBL6724899 0.87 SGK1 (0.48) MCL1CDK1CCNB1CCNA2CCND1
SCHEMBL6716845 0.85 GSPT1 (0.46) GSPT1DDB1CRBNLMNAHSD11B1
SCHEMBL6724595 0.84 GSPT1 (0.44) GSPT1DDB1CRBNCDK1CCNB1
SCHEMBL6716711 0.83 MAPK10 (0.44) GSPT1DDB1CRBNLMNAHSD11B1
SCHEMBL6718834 0.83 SGK1 (0.47) MCL1CDK1CCNB1CCNA2CCND1
SCHEMBL6718224 0.83 EDNRA (0.49) EDNRA
SCHEMBL6720526 0.83 THRB (0.52) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818651-B2 ANTIINFLAMMATORY, ANTIASTHMATIC, SKIN, AND AUTOIMMUNE DISORDERS; CROHN*S DISEASE, ULCERATIVE COLITIS, CONJUCTIVITIS, MULTIPLE SCLEROSIS, AND RHEUMATOID ARTHRITIS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE ALTANA PHARMA AG (DE) 2004-11-16 US disclosed
US-20040044212-A1 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors ALTANA PHARMA AG (DE) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044212-A1 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors PDE7B, PDE3B, PDE3A GSPT1 1717/4885DDB1 1589/4885CRBN 4807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.